EP4688771A1 — Novel fak degrader compounds and uses thereof
Assigned to Bristol Myers Squibb Co · Expires 2026-02-11 · 0y expired
What this patent protects
Provided herein are compounds and compositions thereof that reduce FAK protein levels. In some embodiments, the compounds have structures of Formula I: In some embodiments, the compounds and compositions are provided for treatment of FAK associated diseases such as cancer.
USPTO Abstract
Provided herein are compounds and compositions thereof that reduce FAK protein levels. In some embodiments, the compounds have structures of Formula I: In some embodiments, the compounds and compositions are provided for treatment of FAK associated diseases such as cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.